



PROGRESS AGAINST CANCER

WHEN CHEMOTHERAPY FAILED TO STOP ADRIAN SKINNER'S CANCER, SHE ENROLLED IN A CLINICAL TRIAL FOR PATIENTS WHO HAVE CERTAIN MUTATIONS. ADRIAN, WHO HAD INHERITED LYNCH SYNDROME, HAD THAT BIOMARKER.

THE NEW AMERICAN ASSOCIATION FOR CANCER RESEARCH, CANCER PROGRESS REPORT HIGHLIGHTS DISCOVERIES THAT ARE SAVING LIVES. IN THE YEAR ENDING JULY THIRTY-ONE, TEN OF THE TWENTY F-D-A APPROVALS FOR NEW CANCER TREATMENTS WERE IMMUNOTHERAPIES, INCLUDING THE VERY ONE THAT SUCCESSFULLY TREATED ADRIAN.

OVER THE NEXT SEVERAL YEARS THERE'LL BE THE COLLECTION OF BIG DATA AND YOU'LL SEE A QUICKER ADVANCEMENT OF SUCCESSFUL THERAPIES. FOR EXAMPLE, RIGHT NOW, WE'VE LEARNED THAT LYNCH SYNDROME IS INCREDIBLY RESPONSIVE TO IMMUNE THERAPIES.

THIS PARTICULAR DRUG WORKS BECAUSE OF MY GENETIC DEFECT. THERE ARE ALL SORTS OF GENETIC DEFECTS THAT ARE CAUSING CANCERS. THE RESEARCH TO DO THOSE IS ONLY POSSIBLE IF WE FUND IT.